Overview

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

Status:
Terminated
Trial end date:
2016-04-30
Target enrollment:
Participant gender:
Summary
This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Pharmaceutical Industries, Ltd.
Treatments:
Hormones